ENTRY       D10096                      Drug
NAME        Calaspargase pegol (USAN);
            Calaspargase pegol-mknl;
            Asparlas (TN)
PRODUCT     ASPARLAS (Servier Pharmaceuticals LLC)
SEQUENCE    LPNITILATG GTIAGGGDSA TKSNYTAGKV GVENLVNAVP QLKDIANVKG EQVVNIGSQD
            MNDDVWLTLA KKINTDCDKT DGFVITHGTD TMEETAYFLD LTVKCDKPVV MVGAMRPSTS
            MSADGPFNLY NAVVTAADKA SANRGVLVVM NDTVLDGRDV TKTNTTDVAT FKSVNYGPLG
            YIHNGKIDYQ RTPARKHTSD TPFDVSKLNE LPKVGIVYNY ANASDLPAKA LVDAGYDGIV
            SAGVGNGNLY KTVFDTLATA AKNGTAVVRS SRVPTGATTQ DAEVDDAKYG FVASGTLNPQ
            KARVLLQLAL TQTKDPQQIQ QIFNQY
            (Disulfide bridge: 77-105, 77'-105', 77''-105'', 77'''-105''')
  TYPE      Peptide
SOURCE      Escherichia coli [TAX:562]
REMARK      Product: D10096<US>
EFFICACY    Antineoplastic, Enzyme (L-asparaginase)
  DISEASE   Acute lymphoblastic leukemia [DS:H00001 H00002]
COMMENT     SC-PEG Asparaginase
BRITE       USP drug classification [BR:br08302]
             Antineoplastics
              Antineoplastics, Other
               Calaspargase pegol
                D10096  Calaspargase pegol (USAN)
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10096
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10096
DBLINKS     PubChem: 135626814
///
